In the last trading session, 2.51 million Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares changed hands as the company’s beta touched 1.18. With the company’s per share price at $10.46 changed hands at -$0.36 or -3.33% during last session, the market valuation stood at $601.23M. DNA’s last price was a discount, traded about -515.68% off its 52-week high of $64.40. The share price had its 52-week low at $5.26, which suggests the last value was 49.71% up since then.
Analysts gave the Ginkgo Bioworks Holdings Inc (DNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.83. If we narrow down to specifics, the data shows that 2 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended DNA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Ginkgo Bioworks Holdings Inc’s EPS for the current quarter is expected to be -1.3.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA was in red as seen at the end of in last trading. With action -28.99%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 6.52%, with the 5-day performance at -28.99% in the red. However, in the 30-day time frame, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is -20.64% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need a downside of -60.92% from its current market value. According to analyst projections, DNA’s forecast low is 4.35 with 12 as the target high. To hit the forecast high, the stock’s price needs a -14.72% plunge from its current level, while the stock would need to tank 58.41% for it to hit the projected low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Year-over-year growth is forecast to reach -9.45% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 44.43M. 4 analysts are of the opinion that Ginkgo Bioworks Holdings Inc’s revenue for the current quarter will be 44.24M. The company’s revenue for the corresponding quarters a year ago was 34.76M and 37.94M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 27.83%. The estimates for the next quarter sales put growth at 16.60%.
The 2025 estimates are for Ginkgo Bioworks Holdings Inc earnings to increase by 45.22%, but the outlook for the next 5-year period is at 43.25% per year.
DNA Dividends
Ginkgo Bioworks Holdings Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30.
